Detalles de la búsqueda
1.
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
Blood
; 129(1): 100-104, 2017 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27784674
2.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Blood
; 119(26): 6226-33, 2012 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-22592608
3.
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Eur J Haematol
; 88(3): 260-8, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22023452
4.
Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
J Immunother
; 35(2): 205-13, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22306909
5.
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Eur J Cancer
; 47(2): 206-14, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20971632
6.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol
; 29(18): 2493-8, 2011 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21576633
7.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Science
; 321(5891): 974-7, 2008 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18703743
8.
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood
; 109(11): 4686-92, 2007 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317858
Resultados
1 -
8
de 8
1
Próxima >
>>